参考文献/References:
[1] Cho YM,Wideman RD,Kieffer TJ.Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus[J]. Endocrinol Metab(Seoul), 2013,28(4):262-274.
[2] Amer DA. Standards of medical care in diabetes-2013[J]. Diabetes Care,2013,36(1):S11-S66.
[3] Sheikh-Ali M,Raheja P,Borja-Hart N.Medical management and strategies to prevent coronary artery disease in patients with type 2 diabetes mellitus[J].Postgrad Med,2013,125(1):17-33.
[4] Mima A,Hiraoka-Yamomoto J,Li Q, et al.Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes[J].Diabetes,2012,61(11):2967-2979.
[5] Park CW,Kim HW,Ko SH, et al.Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice[J].J Am Soc Nephrol,2007,18(4):1227-1238.
[6] Li W,Cui M,Wei Y, et al.Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist[J].Cell Physiol Biochem,2012,30(3):749-757.
[7] Liu L,Liu J,Wong WT, et al.Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism[J].Hypertension,2012,60(3):833-841.
[8] Imamura S,Hirai K,Hirai A.The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients[J].Tohoku J Exp Med,2013,231(1):57-61.
[9] Hendarto H,Inoguchi T,Maeda Y, et al.GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases[J].Metabolism,2012,61(10):1422-1434.
[10] Shiraki A,Oyama JI,Komoda H, et al.The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells[J].Atherosclerosis,2012,221(2):375-382.
[11] Kim M,Platt MJ,Shibasaki T, et al.GLP-1 receptor activation and Epac2 Link atrial natriuretic peptide secretion to control of blood pressure[J].Nat Med,2013,19(5):567-575.
[12] Greger R.Physiology of renal Sodium transport[J].Am J Med Sci,2000,319(1):51-62.
[13] Schlatter P,Beglinger C,Drewe J, et al.Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells[J].Regul Pept,2007,141(1-3):120-128.
[14] Rieg T,Gerasimova M,Murray F, et al.Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice[J].Am J Physiol Renal Physiol,2012,303(7):F963-F971.
[15] Linnebjerg H,Kothare PA,Seger M, et al.Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes[J].Int J Clin Pharmacol Ther,2011,49(2):99-108.
[16] Linnebjerg H,Kothare PA,Park S, et al.Effect of renal impairment on the pharmacokinetics of exenatide[J].Br J Clin Pharmacol,2007,64(3):317-327.
[17] Kaakeh Y,Kanjee S,Boone K, et al.Liraglutide-induced acute kidney injury[J].Pharmacotherapy,2012,32(1):e7-e11.
[18] Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification[J].Ann Intern Med,2003,139(2):137-147.
[19] Germino FW.Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review[J].Clin Ther,2011,33(12):1868-1882.